Pharsight

Drugs that contain Ivermectin

1. Sklice patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6103248 ARBOR PHARMS LLC Topical preparation and therapy for head lice
May, 2018

(5 years ago)

US8927595 ARBOR PHARMS LLC Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice
Oct, 2027

(3 years from now)

US8791153 ARBOR PHARMS LLC Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice
Oct, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 07, 2015

Market Authorisation Date: 07 February, 2012

Treatment: For head lice infestations

Dosage: LOTION;TOPICAL

How can I launch a generic of SKLICE before it's drug patent expiration?
More Information on Dosage

SKLICE family patents

Family Patents

2. Soolantra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5952372 GALDERMA LABS LP Method for treating rosacea using oral or topical ivermectin
Sep, 2018

(5 years ago)

US6133310 GALDERMA LABS LP Method of treatment of rosacea
Apr, 2019

(4 years ago)

US8815816 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a day from now)

US8093219 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a day from now)

US8080530 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a day from now)

US8415311 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a day from now)

US11033565 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a day from now)

US8470788 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a day from now)

US7550440 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a day from now)

US9089587 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(9 years from now)

US10206939 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(9 years from now)

US9782425 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(9 years from now)

US9233117 GALDERMA LABS LP Treatment of inflammatory lesions of rosacea with ivermectin
Mar, 2034

(9 years from now)

US9233118 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 19, 2017

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of inflammatory lesions of rosacea.

Dosage: CREAM;TOPICAL

How can I launch a generic of SOOLANTRA before it's drug patent expiration?
More Information on Dosage

SOOLANTRA family patents

Family Patents